Molecular structure of BAY 85-3934, CAS Number: 1154028-82-6
BAY 85-3934 (CAS 1154028-82-6)
Alternate Names:
Molidustat, 1,2-dihydro-2-[6-(4-morpholinyl)-4-pyrimidinyl]-4-(1H-1,2,3-triazol-1-yl)-3H-pyrazol-3-one
CAS Number:
1154028-82-6
Molecular Weight:
314.3
Molecular Formula:
C13H14N8O2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
BAY 85-3934 (CAS 1154028-82-6) References
- Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects. | Flamme, I., et al. 2014. PLoS One. 9: e111838. PMID: 25392999
- Investigational therapies for renal disease-induced anemia. | Schmid, H. and Jelkmann, W. 2016. Expert Opin Investig Drugs. 25: 901-16. PMID: 27122198
- Mass spectrometric characterization of the hypoxia-inducible factor (HIF) stabilizer drug candidate BAY 85-3934 (molidustat) and its glucuronidated metabolite BAY-348, and their implementation into routine doping controls. | Dib, J., et al. 2017. Drug Test Anal. 9: 61-67. PMID: 27346747
- Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia. | Beck, H., et al. 2018. ChemMedChem. 13: 988-1003. PMID: 29485740
- The HIF-PHI BAY 85-3934 (Molidustat) Improves Anemia and Is Associated With Reduced Levels of Circulating FGF23 in a CKD Mouse Model. | Noonan, ML., et al. 2021. J Bone Miner Res. 36: 1117-1130. PMID: 33592127
- Clinical Potential of Hypoxia Inducible Factors Prolyl Hydroxylase Inhibitors in Treating Nonanemic Diseases. | Miao, M., et al. 2022. Front Pharmacol. 13: 837249. PMID: 35281917
- Isoliquiritin apioside relieves intestinal ischemia/reperfusion-induced acute lung injury by blocking Hif-1α-mediated ferroptosis. | Zhongyin, Z., et al. 2022. Int Immunopharmacol. 108: 108852. PMID: 35597117
- The prolyl hydroxylase inhibitor molidustat fails to restore erythropoietin production in the fibrotic kidney. | Schley, G. and Hartner, A. 2022. Acta Physiol (Oxf). 235: e13858. PMID: 35768895
- Drugs That Mimic Hypoxia Selectively Target EBV-Positive Gastric Cancer Cells. | Cordes, BA., et al. 2023. Cancers (Basel). 15: PMID: 36980731
- A network meta-analysis of the efficacy of hypoxia-inducible factor prolyl-hydroxylase inhibitors in dialysis chronic kidney disease. | Chen, J., et al. 2023. Aging (Albany NY). 15: 2237-2274. PMID: 36988549
Inhibitor of:
ASPHD2, HIF PHD, HIF PHD1, HIF PHD2, HIF PHD3, OGFOD3, P4H-TM, PH-4, PHD (peptidyl-proline 4-dioxygenase), PHD1, and RoXaN.Activator of:
ERK 5.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
BAY 85-3934, 5 mg | sc-507384 | 5 mg | $205.00 |